Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED NA

A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers

NCT03573661 · View on ClinicalTrials.gov ↗

Study Summary

The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, tested for quality assurance, sterilized and shipped to the patient's surgeon. The surgeon will then utilize the BCL at the time of resection of the palpable breast cancer.

Conditions Studied

Interventions

  • DEVICE Breast Cancer Locator (BCL)

Study Locations (4)

New Hampshire

  • Cheshire Medical Center — Keene
  • Dartmouth Hitchcock Medical Center — Lebanon
  • St. Joseph Hospital — Nashua

Massachusetts

  • Lahey Hospital & Medical Center (Lahey Clinic) — Burlington

Trial Details

FieldValue
Enrollment Target 18 participants
Start Date 2018-05-24
Est. Completion 2021-04-05
Phase NA

Sponsor

Dartmouth-Hitchcock Medical Center

396 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03573661

The ClinicalTrials.gov registry entry for NCT03573661 describes a study currently listed as completed. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 396 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Palpable Breast Cancer appearing as the primary indexed condition, and to 1 intervention — of which Breast Cancer Locator (BCL) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT03573661 reports 4 study locations spanning 2 distinct geographic areas — top geographies include New Hampshire, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT03573661 about?

NCT03573661 is a clinical study titled "A Pilot Multi-Institutional Study to Evaluate the Accuracy of a Breast Cancer Locator in Patients With Palpable Cancers". The project objective is to determine whether the Breast Cancer Locator (BCL) can safely and effectively localize breast cancers in patients treated at locations distant from the site of BCL manufacture. This information will be transmitted to CairnSurgical, Inc. where the BCL will be fabricated, te...

What is the current status of trial NCT03573661?

This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2018-05-24. Estimated completion is 2021-04-05.

What conditions does trial NCT03573661 study?

This clinical trial studies the following conditions: Palpable Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT03573661?

The interventions under investigation include: Breast Cancer Locator (BCL) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT03573661?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 396 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT03573661 being conducted?

This trial has 4 study locations across Massachusetts, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial